Tetratherix Limited (ASX:TTX)

Australia · Delayed Price · Currency is AUD

7.40

-0.15 (-1.99%)

Jul 30, 2026, 4:10 PM AEST

59.14% (1Y)

Market Cap	400.57M +71.2%
Revenue (ttm)	2.00M +157.2%
Net Income	-11.97M
EPS	-0.31
Shares Out	53.06M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,890
Open	7.58
Previous Close	7.55
Day's Range	7.21 - 7.58
52-Week Range	3.09 - 7.70
Beta	n/a
Analysts	Buy
Price Target	6.12 (-17.3%)
Earnings Date	Aug 27, 2026

About Tetratherix

Tetratherix Limited engages in biomaterial and regenerative medicine business in Australia and internationally. The company manufactures and commercialize medical device in the areas of bone regeneration, tissue spacing, and tissue healing applications through its Tetramatrix platform technology. Tetratherix Limited was incorporated in 2015 and is based in Alexandria, Australia. [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2015

Employees 15

Stock Exchange Australian Securities Exchange

Ticker Symbol TTX

Full Company Profile

Financial Performance

In fiscal year 2025, Tetratherix's revenue was 1.05 million, an increase of 21.88% compared to the previous year's 863,651. Losses were -9.43 million, 269.1% more than in 2024.

Financial Statements

Analyst Summary

According to 3 analysts, the average rating for TTX stock is "Buy." The 12-month stock price target is $6.12, which is a decrease of -17.30% from the latest price.

Price Target

$6.12

(-17.30% downside)

Analyst Consensus: Buy

Stock Forecasts